- Grail (GRAL) stock jumped more than 30% Monday after FDA briefing documents posted ahead of a Wednesday advisory committee meeting suggested the panel is less concerned with safety.
- The FDA panel will determine whether Galleri is safe and effective as a tool to screen patients for early signs of cancer.
- Volkswagen cut its 2026 profit outlook and flagged about €10B in special charges, sending Volkswagen and Porsche shares lower Monday after Friday's decline.
Quotes
“Grail (GRAL) stock catapulted Monday on positive briefing documents ahead of a key Food and Drug Administration meeting slated for Wednesday.”
“Volkswagen (VLKAF) and Porsche (POAHY) shares fell further on Monday, extending Friday’s losses after Volkswagen (VLKAF) cut its 2026 profit outlook and flagged about €10B in special charges”